In additional to surgery, radiation, and traditional chemotherapy, endocrine therapies that inhibit endogenous estrogen production or binding to ER provide a significant survival benefit to luminal breast cancer patients [4, 9, 10]. This evidence concerns the gene ESR1 and breast carcinoma.